Publication Authors:
Arora, P.S.; Wong, C; Baruch, A; Chinn, L; Vaze, A; Sonoda, J; Gelzleichter, T; Chen, S; Lewin-Koh, N; Morrow, L; Boismenu, R
Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, September 2017.
About this Poster:
BFKB8488A is a humanized, effector-less, bispecific antibody designed to activate the receptor for fibroblast growth factor 21 (FGF21) in adipose tissue, the FGFR1/Klothoß complex. Preclinical studies demonstrated that BFKB8488A largely recapitulates the metabolic actions of recombinant FGF21 in rodents and non-human primates. This Phase 1, first-in-human study was performed with obese but otherwise healthy subjects. The primary objectives were safety, tolerability, and pharmacokinetics. Additionally, insulin, glucose, lipids, and other metabolic markers were measured.
